Asset Details
Do you wish to reserve the book?
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Do you wish to request the book?
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
2013
Overview
A dose-finding study showed that CMX001 at an oral dose of 100 mg twice weekly, as compared with placebo, reduced the risk of cytomegalovirus events from 37% to 10% among patients who had undergone hematopoietic-cell transplantation.
Cytomegalovirus (CMV) infection is a common cause of illness after allogeneic hematopoietic-cell transplantation.
1
,
2
CMV seropositivity in transplant recipients is also associated with an increased risk of death after transplantation, despite preemptive and prophylactic strategies with available antiviral agents.
3
–
5
Although valganciclovir is approved for prophylaxis against CMV infection after solid-organ transplantation, its use is limited by myelosuppression, particularly after hematopoietic-cell transplantation.
3
,
6
–
8
Thus, there is an unmet need for effective drugs against CMV infection that have a better safety profile.
CMX001 is an orally bioavailable lipid acyclic nucleoside phosphonate that is absorbed in the small intestine and transported . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antiviral Agents - administration & dosage
/ Antiviral Agents - adverse effects
/ Biological and medical sciences
/ Cytomegalovirus - isolation & purification
/ Cytomegalovirus Infections - epidemiology
/ Cytomegalovirus Infections - prevention & control
/ Cytosine - administration & dosage
/ Cytosine - analogs & derivatives
/ Diarrhea
/ Diarrhea - chemically induced
/ DNA
/ Dose-Response Relationship, Drug
/ Female
/ Hematopoietic Stem Cell Transplantation
/ Humans
/ Male
/ Organophosphonates - administration & dosage
/ Organophosphonates - adverse effects
/ Patients
